L'acétate de médroxyprogestérone est-il efficace contre l'endométriose ?
Oui, il peut réduire la douleur et les lésions associées à l'endométriose.
EndométrioseEfficacité du traitement
Complications
5
#1
Quelles sont les complications possibles de l'acétate de médroxyprogestérone ?
Les complications peuvent inclure des thromboses, des saignements anormaux et des troubles de l'humeur.
ThrombosesSaignements anormaux
#2
Comment reconnaître une thrombose liée au traitement ?
Des douleurs, un gonflement ou une rougeur dans une jambe peuvent indiquer une thrombose.
ThromboseSymptômes
#3
Quels sont les risques de cancer associés à l'acétate de médroxyprogestérone ?
Il peut y avoir un risque accru de cancer du sein et de l'utérus avec une utilisation prolongée.
Cancer du seinCancer de l'utérus
#4
Comment gérer les complications liées au traitement ?
Un suivi médical régulier et des ajustements de traitement sont essentiels pour gérer les complications.
Gestion des complicationsSuivi médical
#5
L'acétate de médroxyprogestérone peut-il affecter la santé mentale ?
Oui, des changements d'humeur et des symptômes dépressifs peuvent survenir chez certains patients.
Santé mentaleChangements d'humeur
Facteurs de risque
5
#1
Quels facteurs augmentent le risque de complications ?
L'obésité, le tabagisme et des antécédents familiaux de maladies thromboemboliques augmentent le risque.
ObésitéAntécédents familiaux
#2
Les femmes âgées sont-elles plus à risque ?
Oui, les femmes de plus de 35 ans, surtout si elles fument, ont un risque accru de complications.
Femmes âgéesComplications
#3
Comment l'hérédité influence-t-elle le risque ?
Des antécédents familiaux de maladies hormonales ou thromboemboliques peuvent augmenter le risque.
HéréditéMaladies hormonales
#4
Le mode de vie influence-t-il le risque de complications ?
Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque.
Mode de vie sédentaireAlimentation
#5
Les antécédents médicaux jouent-ils un rôle ?
Oui, des antécédents de troubles hormonaux ou de maladies cardiovasculaires augmentent le risque.
Antécédents médicauxMaladies cardiovasculaires
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Acétate de médroxyprogestérone : Questions médicales les plus fréquentes",
"headline": "Acétate de médroxyprogestérone : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Acétate de médroxyprogestérone : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-13",
"dateModified": "2025-12-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Acétate de médroxyprogestérone"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Médroxyprogestérone",
"url": "https://questionsmedicales.fr/mesh/D008525",
"about": {
"@type": "MedicalCondition",
"name": "Médroxyprogestérone",
"code": {
"@type": "MedicalCode",
"code": "D008525",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.210.500.745.745.654.829.395.700"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Acétate de médroxyprogestérone",
"alternateName": "Medroxyprogesterone Acetate",
"code": {
"@type": "MedicalCode",
"code": "D017258",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Renee Heffron",
"url": "https://questionsmedicales.fr/author/Renee%20Heffron",
"affiliation": {
"@type": "Organization",
"name": "Department of Global Health, University of Washington, Seattle, Washington, USA."
}
},
{
"@type": "Person",
"name": "Maricianah Onono",
"url": "https://questionsmedicales.fr/author/Maricianah%20Onono",
"affiliation": {
"@type": "Organization",
"name": "Kenya Medical Research Institute, Busia Rd, Kisumu, Kenya."
}
},
{
"@type": "Person",
"name": "Thesla Palanee-Phillips",
"url": "https://questionsmedicales.fr/author/Thesla%20Palanee-Phillips",
"affiliation": {
"@type": "Organization",
"name": "Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Klein St & Esselen St, Hillbrow, Johannesburg, 2001, South Africa."
}
},
{
"@type": "Person",
"name": "Jared M Baeten",
"url": "https://questionsmedicales.fr/author/Jared%20M%20Baeten",
"affiliation": {
"@type": "Organization",
"name": "University of Washington, Seattle, Washington."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Depot medroxyprogesterone acetate and endometrial cancer: A multicenter case-control study.",
"datePublished": "2023-05-15",
"url": "https://questionsmedicales.fr/article/37183712",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ijgo.14846"
}
},
{
"@type": "ScholarlyArticle",
"name": "Medroxyprogesterone acetate-resistant endometrial cancer cells are susceptible to ferroptosis inducers.",
"datePublished": "2023-05-07",
"url": "https://questionsmedicales.fr/article/37160245",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.lfs.2023.121753"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Pilot Study of Adolescent and Young Adult Experience with Subcutaneous Depot Medroxyprogesterone Acetate.",
"datePublished": "2023-06-22",
"url": "https://questionsmedicales.fr/article/37354986",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jpag.2023.06.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Update on the Impact of Depot Medroxyprogesterone Acetate on Vaginal Mucosal Endpoints and Relevance to Sexually Transmitted Infections.",
"datePublished": "2023-06-21",
"url": "https://questionsmedicales.fr/article/37341916",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11904-023-00662-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of the effectiveness of Dienogest with medroxyprogesterone acetate in the treatment of pelvic pain and recurrence of endometriosis after laparoscopic surgery.",
"datePublished": "2023-03-30",
"url": "https://questionsmedicales.fr/article/36995381",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00404-022-06898-2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011083"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072473"
},
{
"@type": "ListItem",
"position": 4,
"name": "Stéroïdes",
"item": "https://questionsmedicales.fr/mesh/D013256"
},
{
"@type": "ListItem",
"position": 5,
"name": "Prégnanes",
"item": "https://questionsmedicales.fr/mesh/D011278"
},
{
"@type": "ListItem",
"position": 6,
"name": "Prégnènes",
"item": "https://questionsmedicales.fr/mesh/D011283"
},
{
"@type": "ListItem",
"position": 7,
"name": "Prégnènediones",
"item": "https://questionsmedicales.fr/mesh/D011282"
},
{
"@type": "ListItem",
"position": 8,
"name": "Médroxyprogestérone",
"item": "https://questionsmedicales.fr/mesh/D008525"
},
{
"@type": "ListItem",
"position": 9,
"name": "Acétate de médroxyprogestérone",
"item": "https://questionsmedicales.fr/mesh/D017258"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Acétate de médroxyprogestérone - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Acétate de médroxyprogestérone",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-02-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Acétate de médroxyprogestérone",
"description": "Comment diagnostiquer un déséquilibre hormonal ?\nQuels symptômes indiquent un besoin d'acétate de médroxyprogestérone ?\nQuels tests sont utilisés pour évaluer l'endométriose ?\nComment évaluer l'efficacité de l'acétate de médroxyprogestérone ?\nQuels signes cliniques nécessitent un traitement hormonal ?",
"url": "https://questionsmedicales.fr/mesh/D017258#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Acétate de médroxyprogestérone",
"description": "Quels sont les effets secondaires courants ?\nComment l'acétate de médroxyprogestérone affecte-t-il le cycle menstruel ?\nQuels symptômes peuvent indiquer une réaction allergique ?\nL'acétate de médroxyprogestérone peut-il causer des saignements ?\nQuels symptômes indiquent une surdose ?",
"url": "https://questionsmedicales.fr/mesh/D017258#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Acétate de médroxyprogestérone",
"description": "Comment prévenir les effets secondaires de l'acétate de médroxyprogestérone ?\nY a-t-il des mesures préventives pour les troubles hormonaux ?\nComment réduire le risque de complications liées au traitement ?\nL'éducation sur les effets du traitement est-elle importante ?\nPeut-on prévenir l'endométriose ?",
"url": "https://questionsmedicales.fr/mesh/D017258#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Acétate de médroxyprogestérone",
"description": "Comment l'acétate de médroxyprogestérone est-il administré ?\nQuelle est la durée du traitement avec l'acétate de médroxyprogestérone ?\nPeut-on utiliser l'acétate de médroxyprogestérone pendant la grossesse ?\nQuels autres traitements sont disponibles pour les troubles hormonaux ?\nL'acétate de médroxyprogestérone est-il efficace contre l'endométriose ?",
"url": "https://questionsmedicales.fr/mesh/D017258#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Acétate de médroxyprogestérone",
"description": "Quelles sont les complications possibles de l'acétate de médroxyprogestérone ?\nComment reconnaître une thrombose liée au traitement ?\nQuels sont les risques de cancer associés à l'acétate de médroxyprogestérone ?\nComment gérer les complications liées au traitement ?\nL'acétate de médroxyprogestérone peut-il affecter la santé mentale ?",
"url": "https://questionsmedicales.fr/mesh/D017258#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Acétate de médroxyprogestérone",
"description": "Quels facteurs augmentent le risque de complications ?\nLes femmes âgées sont-elles plus à risque ?\nComment l'hérédité influence-t-elle le risque ?\nLe mode de vie influence-t-il le risque de complications ?\nLes antécédents médicaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D017258#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un déséquilibre hormonal ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un bilan hormonal et des tests sanguins sont nécessaires pour évaluer les niveaux d'hormones."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un besoin d'acétate de médroxyprogestérone ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des irrégularités menstruelles, des douleurs pelviennes ou des symptômes de ménopause peuvent indiquer ce besoin."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'endométriose ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'échographie, l'IRM et la laparoscopie sont des méthodes courantes pour diagnostiquer l'endométriose."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité de l'acétate de médroxyprogestérone ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par le suivi des symptômes et des cycles menstruels après traitement."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques nécessitent un traitement hormonal ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements anormaux ou des symptômes de ménopause peuvent nécessiter un traitement hormonal."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent des nausées, des maux de tête et des changements d'humeur."
}
},
{
"@type": "Question",
"name": "Comment l'acétate de médroxyprogestérone affecte-t-il le cycle menstruel ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut réguler le cycle menstruel en stabilisant les niveaux d'hormones progestatives."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une réaction allergique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, des démangeaisons ou un gonflement peuvent signaler une allergie."
}
},
{
"@type": "Question",
"name": "L'acétate de médroxyprogestérone peut-il causer des saignements ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des saignements irréguliers peuvent survenir, surtout au début du traitement."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une surdose ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes tels que des douleurs abdominales sévères ou des saignements excessifs peuvent indiquer une surdose."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets secondaires de l'acétate de médroxyprogestérone ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et une communication ouverte avec le médecin peuvent aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour les troubles hormonaux ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain, gérer le stress et consulter régulièrement un médecin sont essentiels."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque de complications liées au traitement ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier et l'ajustement de la posologie peuvent réduire les risques de complications."
}
},
{
"@type": "Question",
"name": "L'éducation sur les effets du traitement est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comprendre les effets et les risques aide les patients à prendre des décisions éclairées."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'endométriose ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode garantie, mais un diagnostic précoce et un traitement peuvent aider."
}
},
{
"@type": "Question",
"name": "Comment l'acétate de médroxyprogestérone est-il administré ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est généralement administré par voie orale ou par injection intramusculaire."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement avec l'acétate de médroxyprogestérone ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée dépend de l'indication, mais elle peut varier de quelques mois à plusieurs années."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'acétate de médroxyprogestérone pendant la grossesse ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il est contre-indiqué pendant la grossesse en raison de risques pour le fœtus."
}
},
{
"@type": "Question",
"name": "Quels autres traitements sont disponibles pour les troubles hormonaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "D'autres options incluent les contraceptifs oraux combinés et les traitements hormonaux substitutifs."
}
},
{
"@type": "Question",
"name": "L'acétate de médroxyprogestérone est-il efficace contre l'endométriose ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut réduire la douleur et les lésions associées à l'endométriose."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de l'acétate de médroxyprogestérone ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent inclure des thromboses, des saignements anormaux et des troubles de l'humeur."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une thrombose liée au traitement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs, un gonflement ou une rougeur dans une jambe peuvent indiquer une thrombose."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de cancer associés à l'acétate de médroxyprogestérone ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut y avoir un risque accru de cancer du sein et de l'utérus avec une utilisation prolongée."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées au traitement ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et des ajustements de traitement sont essentiels pour gérer les complications."
}
},
{
"@type": "Question",
"name": "L'acétate de médroxyprogestérone peut-il affecter la santé mentale ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements d'humeur et des symptômes dépressifs peuvent survenir chez certains patients."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de complications ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, le tabagisme et des antécédents familiaux de maladies thromboemboliques augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les femmes âgées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes de plus de 35 ans, surtout si elles fument, ont un risque accru de complications."
}
},
{
"@type": "Question",
"name": "Comment l'hérédité influence-t-elle le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux de maladies hormonales ou thromboemboliques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque de complications ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de troubles hormonaux ou de maladies cardiovasculaires augmentent le risque."
}
}
]
}
]
}
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
2021-02-22
Department of Molecular and Cell Biology, University of Cape, Cape Town, South Africa; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa. Electronic address: janet.hapgood@uct.ac.za.
Publications dans "Acétate de médroxyprogestérone" :
Department of Pathology and Molecular Medicine, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8P 3Z5, Canada; McMaster Immunology Research Center, McMaster University, Michael G. DeGroote Center for Learning and Discovery, Hamilton, Ontario, L8S 4L8, Canada. Electronic address: kaushic@mcmaster.ca.
Publications dans "Acétate de médroxyprogestérone" :
SCNU Environmental Research Institute, Guangdong Provincial Key Laboratory of Chemical Pollution and Environmental Safety & MOE Key Laboratory of Environmental Theoretical Chemistry, South China Normal University, Guangzhou, 510006, China; State Key Laboratory of Organic Geochemistry, Guangzhou Institute of Geochemistry, Chinese Academy of Sciences, Guangzhou, 510640, China.
Publications dans "Acétate de médroxyprogestérone" :
SCNU Environmental Research Institute, Guangdong Provincial Key Laboratory of Chemical Pollution and Environmental Safety & MOE Key Laboratory of Environmental Theoretical Chemistry, South China Normal University, Guangzhou, 510006, China.
Publications dans "Acétate de médroxyprogestérone" :
SCNU Environmental Research Institute, Guangdong Provincial Key Laboratory of Chemical Pollution and Environmental Safety & MOE Key Laboratory of Environmental Theoretical Chemistry, South China Normal University, Guangzhou, 510006, China.
Publications dans "Acétate de médroxyprogestérone" :
SCNU Environmental Research Institute, Guangdong Provincial Key Laboratory of Chemical Pollution and Environmental Safety & MOE Key Laboratory of Environmental Theoretical Chemistry, South China Normal University, Guangzhou, 510006, China.
Publications dans "Acétate de médroxyprogestérone" :
SCNU Environmental Research Institute, Guangdong Provincial Key Laboratory of Chemical Pollution and Environmental Safety & MOE Key Laboratory of Environmental Theoretical Chemistry, South China Normal University, Guangzhou, 510006, China; State Key Laboratory of Organic Geochemistry, Guangzhou Institute of Geochemistry, Chinese Academy of Sciences, Guangzhou, 510640, China; School of Life Sciences, Guangzhou University, Guangzhou, 510655, China.
Publications dans "Acétate de médroxyprogestérone" :
SCNU Environmental Research Institute, Guangdong Provincial Key Laboratory of Chemical Pollution and Environmental Safety & MOE Key Laboratory of Environmental Theoretical Chemistry, South China Normal University, Guangzhou, 510006, China. Electronic address: guangguo.ying@m.scnu.edu.cn.
Publications dans "Acétate de médroxyprogestérone" :
To assess the associations between depot medroxyprogesterone acetate (DMPA) and endometrial cancer....
This multicenter case-control study was conducted among tertiary hospitals in Thailand. Patients were women with endometrial cancer. Controls were women admitted for other conditions, matched for age ...
During 2015 to 2021, 378 patients and 1134 controls were included. Ever use of DMPA was associated with a 70% decreased overall risk of endometrial cancer (aOR, 0.30 [95% CI, 0.21-0.42]). Endometrial ...
Depot medroxyprogesterone acetate use was inversely associated with endometrial cancer risk in a duration-dependent manner. This association was independent of cancer subtype....
Medroxyprogesterone acetate (MPA) is the most common fertility-sparing treatment in patients with early-stage endometrial cancer. If MPA treatment fails, hysterectomy is recommended. Thus, there is an...
The levels of solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4), the main mediators of ferroptosis, were examined. Cell viability was evaluated after treatment with the f...
The expression of SLC7A11 and GPX4 in MPA-resistant ECC-1 cells decreased in comparison to parental ECC-1 cells. Sulfasalazine, erastin, and RSL3 significantly reduced cell viability and increased int...
Treatment with ferroptosis inducers could be a novel therapeutic approach for MPA-resistant endometrial cancer....
To describe satisfaction with and preference for subcutaneous depot medroxyprogesterone acetate (DMPA-SC), along with adherence and feasibility, in adolescents and young adults (AYAs) METHODS: Survey ...
In this small sample of patients within a children's hospital, the overall experience with DMPA-SC was favorable. Clinicians caring for adolescents should consider including DMPA-SC in counseling when...
The long-acting reversible intramuscularly-injected contraceptive depot medroxyprogesterone acetate (DMPA-IM) is widely used by cisgender women in Africa. Although DMPA-IM provides reliable contracept...
Although previous observational studies found women using DMPA-IM had higher abundance of bacterial vaginosis (BV)-associated bacteria, increased inflammation, increased cervicovaginal HIV target cell...
The aim of this study was to compare the effects of Dienogest and medroxyprogesterone acetate (MPA) on the recurrence of endometriosis lesions and clinical symptoms in women undergoing laparoscopic su...
This single center clinical trial was conducted among 106 women with endometriosis undergoing laparoscopic surgery who candidate receiving post-surgery hormone therapy. Participants were allocated to ...
Finally, data were evaluated based on 48 and 53 women in the Dienogest and MPA groups, respectively. After 6 months follow-up assessments the pelvic pain score was significantly lower in Dienogest gro...
The findings showed that Dienogest treatment has better effect in reducing pelvic pain and the mean size of the recurrent endometriosis lesions after endometriosis laparoscopic surgery when compared t...
Self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception (DMPA-SC) is registered in many countries. It shows great potential for improving contraceptive access, contin...
To describe the implementation strategies to scale up self-administered DMPA-SC and the barriers, facilitators, and outcomes of these programs....
Recent guidelines, including the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for scoping reviews, were used to design and report this review. An article or re...
Of the 755 retrieved documents, 34 were included in this review. Most of the documents included were multi-country reports (n = 14), and all documents were published within the last 5 years (2018-2021...
This scoping review reported a wide range of interventions employed by countries and programs to scale up DMPA-SC self-administration but minimal evidence of the scale-up outcomes. Evidence from this ...
The protocol for this review was registered in the protocols.io repository ( https://www.protocols.io/view/a-protocol-for-a-scoping-review-of-implementation-x54v9yemmg3e/v1 )....
Can medroxyprogesterone acetate (MPA) be used as a pituitary suppressor instead of a gonadotrophin releasing hormone (GnRH) antagonist during ovarian stimulation in elective fertility preservation and...
A multicentre, retrospective, observational, cohort study conducted in 11 IVIRMA centres affiliated to private universities. Of a total of 1652 cycles of social fertility preservation, 267 patients we...
In the social fertility preservation cycles, the number of mature oocytes vitrified in MPA was similar to the number of those treated with an antagonist, a trend that was seen regardless of age (≤35 o...
Administration of PPOS yields similar results to GnRH antagonists in oocytes retrieved, rate of euploid embryos and clinical outcome. Hence, PPOS can be recommended for ovarian stimulation in social f...
The anti-cancer properties of plasma-treated solutions (PTS) and their interaction with drugs are one of the most popular topics in modern plasma medicine. Our research involved comparing the effects ...
In the progestin-primed ovarian stimulation protocol, the oral administration of medroxyprogesterone acetate has been observed to effectively inhibit the LH surge during ovarian stimulation in patient...
This retrospective cohort study included 710 patients who underwent cycles of...
In this study, significant differences were observed among three groups in various parameters including body mass index, baseline levels of Anti-Müllerian hormone and luteinizing hormone, antral folli...
Progestin-primed ovarian stimulation with letrozole using different dose of medroxyprogesterone acetate per day was comparable in terms of the number of oocytes retrieved, the number of high-quality e...
The aim of this study was to evaluate the effects of medroxyprogesterone acetate (MPA) treatment in comparison to those of gonadotropin releasing hormone (GnRH) antagonists for the prevention of prema...